Midatech Group and MonoSol Rx Enter Collaboration Agreement to Unite Nanoparticle and Thin Film Drug Delivery Technologies
Potential to Develop New Oral Drug Candidates with Superior Efficacy, Safety, Convenience, and Commercial Potential
Under terms of the agreement, Midatech Ltd and MonoSol Rx will jointly research, develop and commercialize new drug candidates designed to deliver therapeutic nanoparticles in thin film. Research and development will occur at Midatech Biogune S.L., in Bilbao, Spain with clinical development at a new facility in Basel, Switzerland. MonoSol Rx’s facility in Portage, Indiana is critical in these joint activities. Further terms were not disclosed.
Organizations
Other news from the department business & finance
These products might interest you
DynaPro Plate Reader III by Wyatt Technology
Screening of biopharmaceuticals and proteins with high-throughput dynamic light scattering (DLS)
Efficiently characterize your sample quality and stability from lead discovery to quality control
Eclipse by Wyatt Technology
FFF-MALS system for separation and characterization of macromolecules and nanoparticles
The latest and most innovative FFF system designed for highest usability, robustness and data quality
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.